In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles.
introduction
The role of 18 fluorodeoxyglucose-positron emission tomography (PET) scanning in posttreatment evaluation of aggressive non-Hodgkin's lymphoma (NHL) has been the subject of intense research in the past years. Its diagnostic performances as compared with conventional imaging methods have been systematically reviewed in several meta-analyses [1] [2] [3] [4] . The standardized International Workshop Criteria (IWC) proposed in 1999 [5] , which rely essentially on computed tomography scans for the measurement of tumor lesions, have gained wide acceptance and are commonly used to report treatment results in aggressive NHL. Two studies have specifically reported on the benefits of integrating the results of PET to the widely accepted IWC in the posttreatment evaluation of patients treated with chemotherapy only (without rituximab), showing that integrating PET provides a more accurate response assessment than IWC alone [6, 7] . Revised IWC integrating PET have been proposed for end-of-treatment response assessment [8, 9] . The revised response criteria for predictably PET avid histologies include the following: the new definition for complete response (CR) includes (i) no signs or symptoms of disease; (ii) negative PET; (iii) normal bone marrow. CR unconfirmed (CRu) is no longer included. Partial response (PR) is defined as ‡50% decrease in tumor size, but with a positive PET at prior disease sites (marrow nondeterminant).
As pointed out in these recommendations [8] , except for the use of PET or PET/computed tomography (CT) at completion of therapy in Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL), most recommendations regarding other applications of PET such as early evaluation during treatment [10] [11] [12] are based solely on expert advice, waiting for confirmation in prospective studies. In this particular case, PET interpretation can be refined by using quantitative information such as standard uptake value (SUV) measurements [13] , showing that specific criteria should probably be determined for interim PET analysis.
In aggressive lymphoma therapy, the postinduction period (i.e. when the patient has received the half of planned chemotherapy cycles) is usually the time where a first formal evaluation of treatment efficacy (usually using computed tomography scans) is carried out, in order to decide what kind of consolidative or salvage therapy the patient should receive. Completing our previously published results regarding early PET evaluation at two cycles [11] , we here report on 103 patients with DLBCL prospectively evaluated with PET at the end of induction therapy (three to four courses, three patients with zero age-adjusted International Prognostic Index (aaIPI) risk factors having received only three courses of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (ACVBP) according to standard Groupe d'Etude des Lymphomes de l'Adulte (GELA) practice [14] ) and determine the benefit of integrating PET in response classification using the IWC. As opposed to earlier studies, half of our patients have received rituximab during their treatment in addition to chemotherapy.
patients and methods

patient population and study design
We studied 103 consecutive patients with newly diagnosed DLBCL who had been prospectively enrolled by four departments of hematology of the Assistance Publique-Hô pitaux de Paris (AP-HP), all being involved in the GELA. Patients were evaluated according to IWC and using PET before and after two (early evaluation) and three to four courses of an inductive chemo-or immunochemotherapy regimen (see below). Importantly, the results of PET carried out at any time point did not influence treatment decisions, which were solely based on the IWC criteria. All patients had measurable disease before treatment, were younger than 80 years with an Eastern Cooperative Oncology Group performance status of zero to two. Exclusion criteria were the following: meningeal involvement or primary cerebral lymphoma; positive serology for HIV; concomitant or previous cancer (except in situ cervical carcinoma) and congestive heart failure or liver or kidney failure. The protocol was approved by our Institutional Review Board and all patients gave informed written consent. This study is in accordance with the principles of the declaration of Helsinki. The study was sponsored by the Délégation à la Recherche Clinique de l'AP-HP.
first-line therapeutic strategy
All patients received a doxorubicin-containing regimen as induction treatment, with or without rituximab, as detailed in Table 1 . Treatment principles were as follows: patients >60 years were administered CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or rituximab plus CHOP (R-CHOP) on the basis of eight cycles every 3 weeks according to the LNH98-5 study of the GELA [15] . Patients aged 60 years or younger and presenting with one to three adverse factors of the aaIPI generally received four cycles of CHOP-derived intensified regimens, namely, ACVBP or doxorubicin, cyclophosphamide, etoposide (ACE) delivered every 2 weeks according to a GELA protocol active at that time [16] . After the closure of this protocol, subsequent patients received four cycles of a combination of rituximab and ACVBP (R-ACVBP) as an inductive regimen used in a more recently activated GELA program. Finally, patients aged 60 years or younger presenting with two or three factors of the aaIPI and who reached at least PR on the basis of IWC after induction (with ACVBP, ACE or R-ACVBP) were planned to receive a consolidative high-dose therapy followed by autologous peripheral stem-cell transplantation.
pretreatment and response evaluation
Pretreatment staging and response evaluation at four cycles were on the basis of clinical examination, CT scan of the chest, abdomen and pelvis and bone marrow biopsy (further referred to as conventional diagnostic methods (CDMs)). Patients were classified as showing CR, CRu, PR, stable disease (SD) ((i) less than 50% decrease and less than 50% increase in PET imaging modalities and image analysis-PET response criteria
The first 91 patients were scanned on a dedicated C-PET camera (ADAC). They were injected with 2 MBq/kg 18 FDG and sat at rest for 83 6 22 min before imaging. The acquisition consisted of five to seven overlapping bed shifts, to cover a volume from the upper thigh to the skull base (25-cm field of view). For each bed position, a 6-min emission scan was acquired in a three-dimensional coincidence mode, followed by a 1-min transmission scan (137Cs source). The last 12 patients were scanned on a Gemini PET/CT system (Philips). They were injected with 5 MBq/kg 18 FDG and rested for 69 6 9 min before imaging. The acquisition featured a lowdose transmission CT scan (100 kV; 40 mAs; slice thickness, 5 mm), followed by the emission scan in 9-11 overlapping bed shifts (18-cm field of view), each of 3-min duration. In each case, images were reconstructed iteratively with and without attenuation correction. Images were interpreted by a consensus of two experienced observers blinded to clinical, radiologic and follow-up data. Each postchemotherapy scan was scored as negative or positive according to previously reported criteria [11] . All foci of abnormal FDG uptake were scored for their extent and intensity using a three-point scale (1 = low, 2 = moderate, 3 = high) within each lymphatic area, organ or skeletal region. Then, each postchemotherapy scan was scored as negative or positive. Negative was defined as having no residual abnormal uptake or as having a unique residual site (with an extent score of 1) associated with an intensity score of 1, whereas all the other previously hypermetabolic sites were extinguished. Positive was defined as having at least one residual site (with an extent score of 1) associated with an intensity score of 2 or as having two or more residual sites with any extent and intensity scores. Whenever possible, the maximal standardized uptake value (SUV max) on a given PET was calculated as previously described [13] .
follow-up
Restaging was carried out on the basis of CDMs at the end of treatment, then every 6 months during 2 years and then yearly during 3 years. The patient's status was assessed using standardized guidelines.
statistical analyses
Patient characteristics and response rates were compared using the chi-squared test. Overall survival was calculated from the beginning of treatment to death from any cause or last follow-up. Event-free survival (EFS) was calculated from the beginning of treatment to disease progression, relapse, death from any cause or last follow-up. Progression-free survival was calculated from the beginning of treatment to disease progression, death from lymphoma or last follow-up [5] . Survival curves were estimated using the method of Kaplan and Meier and compared using the log-rank test [17] . Differences between the results of comparative tests were considered significant at a two-sided P < 0.05. All statistical analyses were carried out using Statistical Application System software (SAS, version 9, SAS Institute, Cary, NC).
results
patient characteristics
The demographic and pretreatment characteristics of the 103 patients are shown in Table 1 . The majority of patients (76%) were <60, and all groups of the aaIPI were represented, with only a minority of very low-risk patients: no aaIPI poor-risk factors 4 of 103(4%); one factor 36 of 103 (35%); two factors 36 of 103 (35%); three factors 278 of 103 (26%).
The diagnosis of DLBCL was on the basis of histopathology and immunohistochemistry according to the World Health Organization classification criteria [18] and confirmed upon review by an experienced hematopathologist in all cases. In addition, diagnostic specimens with sufficient available material were stained with antibodies against Bcl2, CD10, Bcl6 and MUM1 and then classified as having a germinal center or postgerminal center phenotype according to previously reported criteria [19] . Due to limited availability of diagnostic tissue and technical constraints, only 95 patients had an interpretable Bcl-2 staining, and only 73 could be classified as having a germinal center versus nongerminal center phenotype. No significant differences were observed between patients having a positive versus negative postinduction PET scan regarding the main clinical and biological characteristics.
response assessment
All patients except four could be evaluated after induction therapy, thus leaving 99 assessable patients: two patients died from infectious complications during induction, one showed clinical progression after two chemotherapy courses and one presented multiple complications precluding the continuation of chemotherapy. After induction, according to the 1999 IWC, 23% had a CR, 54% had a CRu, 15% had a PR, 2% had SD and 5% showed PD. The same 99 patients were evaluated through PET after a median delay of 18 days from their previous treatment course. Table 2 shows the correspondence between the IWC and IWC + PET response designations. Altogether, 76 of 99 (77%) patients showed concordant results, while they were discordant in 23 of 99 (23%).
Concordance was excellent inside the IWC CR category, with no patient showing residual abnormalities by PET while having no detectable abnormalities also by CDM. Among CRu patients, 44 of 54 (81%) had no residual PET abnormalities and were thus classified as complete responders. None of these patients were classified as CRu because of an indeterminate 18 FDG uptake and were thus reclassified as partial responders. Of note, one CRu patient was classified as having PD according to PET. This was because the interpretation of PET took into account the results of early PET and that patient showed significant increase in intensity of a splenic lesion between the early and postinduction PET examinations. No biopsy was carried out, and the patient went on to consolidative high-dose therapy as planned according to IWC response evaluation. She is in continuous CR at last follow-up.
Nine of 15 (60%) IWC PR patients were reclassified as CRs by PET, while four had residual abnormalities on PET, confirming their PR status. Here again, two IWC PR patients were reclassified as PD on the basis of the comparison of early and postinduction PET examinations. One of them presented new bone lesions not detected by conventional CT scan. Unfortunately, both patients died from complications unrelated to their lymphoma. Among the two IWC SD patients in this series, one was classified as CR according to PET (no residual abnormalities). Unexpectedly, he rapidly relapsed and died in a situation of uncontrolled disease. The other patient also progressed and is now in continuous CR after a salvage treatment having included an allogeneic stem-cell transplant.
Interestingly, there were no significant differences in the proportion of patients showing a discordant/concordant response between patients having or not received rituximab.
SUV calculations were available for 86 patients. The median SUV max was 13.6 (range 5.2-24.6) before treatment in the group treated without rituximab and 3.2 (1.4-20.9) in the same group after four cycles. In the group treated with rituximab, the values were 10.2 (1.0-23.3) and 2.1 (0.9-9.4), respectively.
survival analysis
An EFS analysis was carried out with a stopping date (10% missing events) fixed at February 2007. Median follow-up was 53 months. Survival curves are depicted in Figure 1 . Patients having a negative PET had an estimated 5-year EFS of 80% if they were in CR or CRu according to IWC (n = 65) and of 70% if in less than CR/CRu (n = 10). Patients with a positive PET had an estimated 5-year EFS of 58% if in CR/CRu according to IWC (n = 12), and of 0% if in less than CRu (n = 12). Differences were highly significant (P < 0.0001) according to the log-rank test.
The risk of disease progression was better evaluated when integrating PET to treatment evaluation. Among 78 patients in CR or CRu according to IWC, 15 (19%) progressed, while this was only the case of 4 of 72 (5%) PET CR patients. In case of a PR as evaluated by IWC, 6 of 15 (40%) progressed, while this was the case for 8 of 13 PR patients (61%) as evaluated by PET. discussion 18 FDG-PET for aggressive lymphomas has mainly been evaluated in the fields of pretreatment staging, early evaluation during treatment and posttreatment evaluation. Its value in other domains, such as follow-up after remission or postinduction restaging, remains to be evaluated. Our study represents a comprehensive analysis of a series of patients with DLBCL evaluated through postinduction PET scans and comparing the value of PET to the established IWC in this setting.
Our findings confirm after induction what has been shown at end of treatment by Cheson et al., showing that integrating PET provides a more accurate evaluation than the classical IWC alone. Our interpretation criteria for PET negativity, as defined per protocol, slightly differed from those proposed in the revised response criteria. The latter consider a PET examination to be negative if no abnormal fixation (above mediastinal blood pool) is detected. Our criteria considered PET scans showing residual fixation of low intensity in a single site to be negative. All patients being in CR according to IWC also were in CR according to PET.
As most of our patients have undergone an early PET study (after two cycles), its results were used to interpret the postinduction PET. Thus, four patients were considered to have progressive disease on the basis of increasing lesion size and/or intensity between both examinations, although they would have been classified as having a PR if only the postinduction study had been taken into account. As patient numbers are low, it is difficult to draw any conclusions on this group, but two patients rapidly progressed and the two others received high-dose therapy before reaching a CR. Conversely, all patients (n = 60) with a negative PET after two cycles remained negative after four. The outcome of patients converting from a positive PET after two cycles to a negative PET after four seemed slightly disadvantageous in comparison to that of patients with a negative PET after two and four cycles, with 4 of 14 (28%) patients showing an event in the former group and 11 of 58 (19%) in the latter. This should also be interpreted with caution given the low number of patients considered.
To conclude, the results of the present study suggest that it may be possible to use PET to identify poor responding patients to induction therapy in order to modify their original article Annals of Oncology treatment accordingly. This approach is currently investigated in an ongoing GELA trial dedicated to patients <60 years with two or three aaIPI risk factors. In this trial, PET assessment is carried out at baseline and after two and four induction cycles. Further treatment is given according to response assessment by PET. Patients who have a positive PET after four cycles leave the study to receive salvage therapy; those who are negative after both the second and fourth cycle continue their planned treatment (without transplant) while those having a positive PET at two cycles, but a negative PET at four cycles receive a more intensive treatment based on Z-BEAM ( 90 Yttrium ibritumomab tiuxetan added to BEAM conditioning regimen) with autologous stem-cell transplant [20] . The results of this trial should help to determine the value of using PET-based response assessment in the course of induction therapy to modify the strategy and also the role of 90 Yttrium ibritumomab tiuxetan plus BEAM as a consolidation therapy in poor-risk patients with DLBCL.
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